StockData

ProKidney vs SAB Biotherapeutics

PROK and SABS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PROK and SABS compare

ProKidney is the larger company, worth 1.2 times as much as SAB Biotherapeutics ($314M against $273M).

ProKidney scores higher on the StockData Score (5 against 4 for SAB Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPROKSABS
Size and price
Market cap$314M$273M
Share price$1.04$3.00
Change, 1 year−54.4%−3.2%
Change, 5 years−89.5%−97.1%
Beta (5Y)2.021.04
Employees23186
StockData Score
Total score5 (better)4
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score4 (better)2
Dividend score00
Valuation
P/S384×–
P/B–1.3×
FCF yield−50.8%–
Growth
Revenue growth (TTM)55.2%–
Profitability
Operating margin−21665%–
Net margin−10288%–
FCF margin−19527%–
Return on equity–−11.3%
Return on invested capital–−95.8%
Financial health
Interest coverage−9327.2×−310.3× (better)
Current ratio8.369.22 (better)
Altman Z-score−1.755.59 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield−7.7%–
Shareholder yield−7.7%0.00% (better)
Ownership
Held by institutions16.1%75.2%
Held by insiders62.9%30.2%
Insider net buying, 12 months−$1.1M–
Short interest, % of float21.7%7.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.